Retapamulin for impetigo and other infections.
Article Details
- CitationCopy to clipboard
Authors unspecified
Retapamulin for impetigo and other infections.
Drug Ther Bull. 2008 Oct;46(10):76-9. doi: 10.1136/dtb.2008.09.0023.
- PubMed ID
- 18832258 [ View in PubMed]
- Abstract
Last year, we concluded that topical fusidic acid should be first-line treatment for impetigo. Since then, retapamulin ointment (Altargo - GlaxoSmithKline), a new antibacterial, has been licensed in the European Union as a short-term treatment for impetigo and infected small lacerations, abrasions or sutured wounds in people aged 9 months or above. Advertisements claim that the product "treats localised impetigo in just 5 days"; by comparison, the British National Formulary (BNF) advises a 7-day course of fusidic acid. Here we consider the place of retapamulin in impetigo and its other licensed indications.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Retapamulin 50S ribosomal protein L3 Protein Streptococcus pyogenes serotype M1 YesInhibitorDetails